{"url_path":"/sec/gyre/8-k/2026-07-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028564-index.html","accession_number":"0001140361-26-028564","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028564-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":108,"has_tables":true,"body_markdown":"Item 2.02.\n\nResults of Operations and Financial Condition.\n\nThis Amendment No. 1 includes (i) the financial statements of Cullgen as of and for the three months ended March 31, 2026 and the year ended December 31, 2025, and (ii) the\nunaudited pro forma condensed combined balance sheet of Gyre and Cullgen as of March 31, 2026 and the unaudited pro forma condensed combined statement of operations of Gyre and Cullgen for the three months ended March 31, 2026 and the year ended\nDecember 31, 2025 and the related notes.\n\nThe information set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference."}